Understanding REMIX Data and Remibrutinib in CSU

Physician’s Summary:
Jason Hawkes, MD, MS, a board-certified dermatologist and associate professor of Dermatology at the University of California Davis, presents data from long-term studies of remibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, noting its favorable efficacy and tolerability profile over 52 weeks in patients with CSU. He explains that initial improvements may be seen within days and that, by 12 weeks, about half of patients achieve "well-controlled" disease, with a third experiencing complete symptom control. By 24 to 52 weeks, rates of complete or well-controlled disease further improve, approaching 50% of patients.

Hawkes emphasizes the 52-week safety profile of remibrutinib is reassuring, with only a minority of patients experiencing bleeding-related adverse events warranting discontinuation. The medication's rapid onset and sustained efficacy make it a promising option for patients in need of immediate and long-term relief from CSU symptoms.

He also addresses the need for perioperative management, advising interruption of remibrutinib pre- and post-surgery for more invasive procedures. Overall, Hawkes concludes that remibrutinib offers robust clinical benefits for CSU patients, with straightforward risk management and a safety profile comparable to other modern targeted therapies.